20:14 , Jun 15, 2018 |  BC Week In Review  |  Clinical News

Eisai, Purdue's insomnia candidate does not impair driving in Phase I

Eisai Co. Ltd. (Tokyo:4523) and Purdue Pharma L.P. (Stamford, Conn.) reported top-line data from the Phase I Study 106 showing that insomnia candidate lemborexant (E2006) given each night at bedtime met the primary endpoint of...
18:20 , Jun 15, 2018 |  BC Week In Review  |  Clinical News

Eisai, Purdue's insomnia candidate improves postural stability in Phase I

Eisai Co. Ltd. (Tokyo:4523) and Purdue Pharma L.P. (Stamford, Conn.) reported top-line data from the Phase I Study 108 showing that both doses of insomnia candidate lemborexant (E2006) given each night at bedtime met the...
17:58 , Mar 30, 2018 |  BC Week In Review  |  Company News

Indivior licenses preclinical addiction candidate from C4X Discovery

C4X Discovery Holdings plc (LSE:C4XD) licensed to Indivior plc (LSE:INDV) exclusive, worldwide rights to C4X3256, a preclinical compound to treat addiction. C4X will receive $10 million up front and is eligible for up to $284...
19:07 , Mar 29, 2018 |  BC Extra  |  Company News

C4X gains after addiction deal with Indivior

C4X Discovery Holdings plc (LSE:C4XD) jumped 56p (99%) to 112.5p after licensing to Indivior plc (LSE:INDV) exclusive, worldwide rights to C4X3256, a preclinical compound to treat addiction. C4X will receive $10 million up front and...
18:43 , Mar 16, 2018 |  BC Week In Review  |  Clinical News

Eisai, Purdue's lemborexant meets in Phase III for insomnia

Eisai Co. Ltd. (Tokyo:4523) and Purdue Pharma L.P. (Stamford, Conn.) reported top-line data from the Phase III SUNRISE 1 trial in about 1,000 patients ages 55 and older with insomnia showing that oral lemborexant (E2006)...
20:04 , Jan 4, 2018 |  BC Innovations  |  Translation in Brief

Designing specificity

Solving a key problem in the orexin field, C4X Discovery Holdings plc (LSE:C4XD) has described how its technology platform yielded an antagonist with selectivity for OX1R over OX2R and disclosed data for the compound in...
16:28 , Jun 27, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Excessive sleepiness Mouse studies suggest agonizing OX2R could help treat narcolepsy. In a mouse model of narcolepsy, intracerebroventricular or intraperitoneal (i.p.) injection of a previously reported OX2R agonist decreased the number of episodes of cataplexy-like...
19:20 , Jun 2, 2017 |  BC Week In Review  |  Company News

Minerva, J&J revise MIN-202 insomnia deal

Minerva Neurosciences Inc. (NASDAQ:NERV) and the Janssen Pharmaceutica N.V. subsidiary of Johnson & Johnson (NYSE:JNJ) amended a 2014 deal to co-develop and commercialize orexin 2 receptor (OX2R; HCRTR2) antagonist MIN-202. Minerva will gain global development...
23:21 , Jun 1, 2017 |  BC Extra  |  Company News

Revision to J&J insomnia deal boosts Minerva shares

Minerva Neurosciences Inc. (NASDAQ:NERV) gained $1.75 (21%) to $10 after amending a 2014 deal with the Janssen Pharmaceutica N.V. subsidiary of Johnson & Johnson (NYSE:JNJ) to co-develop and commercialize orexin 2 receptor (OX2R; HCRTR2) antagonist...
23:21 , Nov 10, 2016 |  BC Week In Review  |  Clinical News

Lemborexant: Ph II started

Eisai began the double-blind, placebo-controlled, international Phase II Study 202 to evaluate 2.5, 5, 10 and 15 mg oral lemborexant for 4 weeks in about 125 patients ages 65-90 with ISWRD and mild to moderate...